# Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma

> **NCT03828448** · PHASE2 · TERMINATED · sponsor: **TG Therapeutics, Inc.** · enrollment: 34 (actual)

## Conditions studied

- Follicular Lymphoma
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Ublituximab
- **DRUG:** Umbralisib

## Key facts

- **NCT ID:** NCT03828448
- **Lead sponsor:** TG Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-10
- **Primary completion:** 2022-05-16
- **Final completion:** 2022-05-31
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Strategic/Business Decision
- **Last updated:** 2023-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03828448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03828448, "Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03828448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*